Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Inclusion Criteria:

• Have met clinical diagnostic criteria for typical CIDP (including incomplete typicalCIDP) or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline onDiagnosis and Treatment of CIDP.

• Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNSguideline on diagnosis and treatment of CIDP.

• Are currently on, and have been receiving chronic, stable doses of systemiccorticosteroids (i.e., daily or every other day oral or pulse regimen), orimmunoglobulin therapy (IVIg or SCIg) ± corticosteroid therapy (either low dose oralcorticosteroids or pulse corticosteroids) for at least 3 months for the treatment ofCIDP at the time of the Screening Visit.

Additional inclusion criteria are defined in the protocol.

Exclusion Criteria:

• Have current or prior history of IgM paraproteinemia with or withoutanti-myelin-associated-glycoprotein antibodies.

• Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy perthe EAN/PNS guideline on diagnosis and treatment of CIDP.

• Have polyneuropathy of causes other than CIDP including but not limited to:

• Multifocal motor neuropathy

• Hereditary demyelinating neuropathy

• Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skinchange syndromes (i.e., POEMS)

• Lumbosacral radiculoplexus neuropathy

• Systemic illnesses including vitamin deficiency syndromes and paraneoplasticneuropathies

• Drug- or toxin-induced

• Have diabetes mellitus (DM) and meets any of the following criteria:

• Does not have both typical CIDP and strong evidence of demyelination on nerveconduction study.

• In the opinion of the Investigator, there is evidence of poorly controlled DMpreceding the diagnosis of CIDP.

• In the opinion of the Investigator, there is evidence of poorly controlled DMat screening.

• Have a history of myelopathy or evidence of central demyelination. Additionalexclusion criteria are defined in the protocol.